Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects
Condition(s):Relapsed or Refractory Diffuse Large B-cell LymphomaLast Updated:October 11, 2023Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Relapsed or Refractory Diffuse Large B-cell LymphomaLast Updated:October 11, 2023Active, not recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-Cell LymphomaLast Updated:December 11, 2023Recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-cell LymphomaLast Updated:March 17, 2023Terminated
Condition(s):Relapsed/Refractory Diffuse Large B Cell LymphomaLast Updated:November 30, 2022Recruiting
Condition(s):Lymphoma, Large B-Cell, Diffuse; Gene Expression ProfilingLast Updated:April 8, 2022Completed
Condition(s):Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell LymphomaLast Updated:July 20, 2023Recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Last Updated:March 29, 2023Active, not recruiting
Condition(s):Diffuse Large B-cell LymphomaLast Updated:October 12, 2022Not yet recruiting
Condition(s):Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Last Updated:March 7, 2024Active, not recruiting
Condition(s):Refractory Diffuse Large B Cell LymphomaLast Updated:March 6, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.